Campus

For US Healthcare Professionals only

Beyfortus® logo

Request a Representative

Menu

Register Now!

To help prepare for the 2024-2025 Respiratory Syncytial Virus (RSV) season, we are excited to offer our Expert Series once again. This year, we are offering two 1-hour events featuring a 45-minute presentation followed by a 15-minute interactive Q&A about Beyfortus.

Join Beyfortus® Expert Series:

RSV LRTI Prevention for Infants

Beyfortus is the first and only long acting antibody indicated for the prevention of RSV lower respiratory tract disease in1:

  • Neonates and infants born during or entering their first RSV season

  • Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season

Each event will feature leading key opinion leaders (KOLs) from the RSV community with diverse backgrounds and experiences, including pediatricians, obstetricians and gynecologists (OB/GYNs), and nurses in both clinic and hospital settings.
This live webinar format provides the opportunity to learn and interact with the leading experts about integrating Beyfortus into your practice.

Registration is now open for the following events:

Event 2: Implementing Beyfortus Into Clinical Practice on September 10th, 2024 at 6:00-7:00 PM ET, featuring:

Zubin Shah, MD, FAAP

  • Neonatologist
  • Baylor University Medical Center at Pediatrics Medical Group
  • TX

Beyfortus Expert Series: RSV LRTI Prevention for Infants

Register now

We look forward to your participation!

 

LRTI, lower respiratory tract infection; OB/GYN, obstetrics and gynecology; RSV, respiratory syncytial virus

Important Safety Information

Contraindication
Beyfortus is contraindicated in infants and children with a history of serious hypersensitivity reactions, including anaphylaxis, to nirsevimab-alip or to any of the excipients.

Warnings and Precautions

  • Hypersensitivity Reactions Including Anaphylaxis: Serious hypersensitivity reactions have been reported following Beyfortus administration. These reactions included urticaria, dyspnea, cyanosis, and/or hypotonia. Anaphylaxis has been observed with human immunoglobulin G1 (IgG1) monoclonal antibodies. If signs and symptoms of anaphylaxis or other clinically significant hypersensitivity reactions occur, initiate appropriate treatment.

  • Use in Individuals with Clinically Significant Bleeding Disorders: As with other IM injections, Beyfortus should be given with caution to infants and children with thrombocytopenia, any coagulation disorder or to individuals on anticoagulation therapy.

Most common adverse reactions with Beyfortus were rash (0.9%) and injection site reactions (0.3%).

Indication

Beyfortus is indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in:

  • Neonates and infants born during or entering their first RSV season.
  • Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.

Please see full Prescribing Information.

Click here to learn more about Sanofi’s commitment to fighting counterfeit drugs.

Important Safety Information

Indication

Reference: 1. Beyfortus (nirsevimab). Prescribing Information. Sanofi.

MAT-US-2310578-v6.0-07/2024

Back to top
sanofi_campus_logo
Back to top
SitemapLegal NoticePrivacy PolicyCookie PolicyDo Not Sell or Share My Personal InformationContact
© 2024 Sanofi. All rights reserved.